In recent times, there have been significant advancements in the cancer treatment sector within Asia, garnering increased attention from investors. According to Statista, the market for oncology drugs in Asia is expected to undergo substantial revenue growth, with an estimated value of US$44.87 billion by 2024 and US$76.66 billion by the end of 2028.
Moreover, the global cancer immunotherapy market reached US$118.9 billion in 2023 and is expected to grow up to US$261 billion by 2032.
The escalating number of cancer cases in Asia has drawn considerable interest, with a forecast of over 35 million new cases globally by 2050. Companies like SunHo Biologics and AstraZeneca are actively involved in working and investing in Asia, affirming the prevailing trend.
During his recent visit to Asia, LongeVC's Garri Zmudze had the opportunity to engage in a discussion with Andrew Tjaardstra from Finance Asia regarding this and the broader longevity space.
You can check Andrew’s recent article on this topic, including Garri’s commentary, here.
Moreover, the global cancer immunotherapy market reached US$118.9 billion in 2023 and is expected to grow up to US$261 billion by 2032.
The escalating number of cancer cases in Asia has drawn considerable interest, with a forecast of over 35 million new cases globally by 2050. Companies like SunHo Biologics and AstraZeneca are actively involved in working and investing in Asia, affirming the prevailing trend.
During his recent visit to Asia, LongeVC's Garri Zmudze had the opportunity to engage in a discussion with Andrew Tjaardstra from Finance Asia regarding this and the broader longevity space.
You can check Andrew’s recent article on this topic, including Garri’s commentary, here.